Taizhou Crene Biotechnology Co., Ltd.
                                                                                                           
Verified Supplier
19 Years
Since 2007
Menu
Chemicals Organic Intermediate

Highly Selective CDK Inhibitors BS-181 Cas 1092443-52-1

Price Negotiable
Price: Negotiable
MOQ: Negotiable
Delivery Time: Negotiable
Product Description

Highly Selective CDK Inhibitors BS-181 Cas 1092443-52-1

 

+ AII PRODUCTS

- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others

 

Product

Size

Price

Stock

Quantity

Get Quotation Now Add to Cart Bulk Inquiry

 

AddThis Sharing Buttons

Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

 

Chemical Information

Product name:BS-181

Purity:98% min

CAS NO:1092443-52-1

Solubility:DMSO50 mg/mL (131.40 mM)

Molecular Formula:C22H33ClN6

Package:Package according to customer requirements

Molecular Weight:416.991

Storage:Store at -20℃

 

Quality control

Remarks

BS-181 is a highly selective CDK inhibitor for CDK7 with an IC(50) of 21 nmol/L. Testing of other CDKs as well as another 69 kinases showed that BS-181 only inhibited CDK2 at concentrations lower than 1 micromol/L, with CDK2 being inhibited 35-fold less potently (IC(50) 880 nmol/L) than CDK7. In MCF-7 cells, BS-181 inhibited the phosphorylation of CDK7 substrates, promoted cell cycle arrest and apoptosis to inhibit the growth of cancer cell lines, and showed antitumor effects in vivo.

 

Related Products

BMS-265246; LDC000067; Ribociclib; SU9516; Purvalanol A; Alvocidib; AZD-5597; Kenpaullone; ON123300; JSH-150; Riviciclib

 

References

[1].Ali S et al. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res. 2009 Aug 1;69(15):6208-15.

[2].Wang BY, et al. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer. Drug Des Devel Ther. 2016 Mar 16;10:1181-9.

Get in Touch

Have questions about our products or want to discuss a custom order? Our team is ready to help you.

Company Taizhou Crene Biotechnology Co., Ltd.
Location Add: Economic Developed Zone of Taizhou Zhejiang China.

Request A Quote

Please check your email address.
Your message must be at least 20 characters.